These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 23027189)

  • 1. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease.
    van Ingen J; Totten SE; Helstrom NK; Heifets LB; Boeree MJ; Daley CL
    Antimicrob Agents Chemother; 2012 Dec; 56(12):6324-7. PubMed ID: 23027189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin.
    Ferro BE; Meletiadis J; Wattenberg M; de Jong A; van Soolingen D; Mouton JW; van Ingen J
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1097-105. PubMed ID: 26643335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria.
    Shen GH; Wu BD; Hu ST; Lin CF; Wu KM; Chen JH
    Int J Antimicrob Agents; 2010 Apr; 35(4):400-4. PubMed ID: 20138481
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Luo J; Yu X; Jiang G; Fu Y; Huo F; Ma Y; Wang F; Shang Y; Liang Q; Xue Y; Huang H
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.
    Heidarieh P; Mirsaeidi M; Hashemzadeh M; Feizabadi MM; Bostanabad SZ; Nobar MG; Hashemi Shahraki A
    Microb Drug Resist; 2016 Mar; 22(2):172-8. PubMed ID: 26468990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antimicrobial susceptibility of non-tuberculous mycobacteria.
    Cowman S; Burns K; Benson S; Wilson R; Loebinger MR
    J Infect; 2016 Mar; 72(3):324-31. PubMed ID: 26723913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine.
    Rastogi N; Goh KS; Bryskier A; Devallois A
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2483-7. PubMed ID: 8913450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial Susceptibility Distributions of Clinical Isolates of Nontuberculous Mycobacteria in Israel.
    Hershko Y; Adler A
    Microb Drug Resist; 2023 Jul; 29(7):302-308. PubMed ID: 37219996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of PBTZ169 and pretomanid against Mycobacterium avium,
    Zheng L; Qi X; Zhang W; Wang H; Fu L; Wang B; Chen X; Chen X; Lu Y
    Front Cell Infect Microbiol; 2023; 13():1115530. PubMed ID: 37077530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activities of Dual Combinations of Antibiotics Against Multidrug-Resistant Nontuberculous Mycobacteria Recovered from Patients with Cystic Fibrosis.
    Schwartz M; Fisher S; Story-Roller E; Lamichhane G; Parrish N
    Microb Drug Resist; 2018 Oct; 24(8):1191-1197. PubMed ID: 29368988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacies of omadacycline + amikacin + imipenem and an all-oral regimen omadacycline + clofazimine + linezolid in a mouse model of
    Ignatius EH; Rimal B; Panthi CM; Belz DC; Lippincott CK; Deck DH; Serio AW; Lamichhane G
    mSphere; 2024 Jul; 9(7):e0038124. PubMed ID: 38980071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial susceptibility and minimum inhibitory concentration distribution of common clinically relevant non-tuberculous mycobacterial isolates from the respiratory tract.
    He G; Wu L; Zheng Q; Jiang X
    Ann Med; 2022 Dec; 54(1):2500-2510. PubMed ID: 36120867
    [No Abstract]   [Full Text] [Related]  

  • 13. Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan.
    Huang CW; Chen JH; Hu ST; Huang WC; Lee YC; Huang CC; Shen GH
    Int J Antimicrob Agents; 2013 Mar; 41(3):218-23. PubMed ID: 23312605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of amikacin in the treatment of nontuberculous mycobacterial disease.
    Raaijmakers J; Schildkraut JA; Hoefsloot W; van Ingen J
    Expert Opin Pharmacother; 2021 Oct; 22(15):1961-1974. PubMed ID: 34292097
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro interaction of some drug combinations to inhibit rapidly growing mycobacteria isolates from cats and dogs and these isolates' susceptibility to cefovecin and clofazimine.
    Bennie CJ; To JL; Martin PA; Govendir M
    Aust Vet J; 2015; 93(1-2):40-5. PubMed ID: 25622709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug susceptibility profiling and genetic determinants of drug resistance in Mycobacterium simiae isolates obtained from regional tuberculosis reference laboratories of Iran.
    Daneshfar S; Khosravi AD; Hashemzadeh M
    PLoS One; 2022; 17(8):e0267320. PubMed ID: 35960778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Activity and Clinical Outcomes of Clofazimine for Nontuberculous Mycobacteria Pulmonary Disease.
    Kim DH; Kim BG; Kim SY; Huh HJ; Lee NY; Koh WJ; Kim H; Kwon OJ; Jhun BW
    J Clin Med; 2021 Oct; 10(19):. PubMed ID: 34640599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria.
    Wallace RJ; Brown-Elliott BA; Crist CJ; Mann L; Wilson RW
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3164-7. PubMed ID: 12234839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Clofazimine and TB47 Combination Activity against Mycobacterium abscessus Using a Bioluminescent Approach.
    Liu Y; Tan Y; Islam MM; Cao Y; Lu X; Zeng S; Hameed HMA; Zhou P; Cai X; Wang S; Mugweru JN; Zhang G; Yin H; Liu J; Nuermberger E; Zhang T
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31843996
    [No Abstract]   [Full Text] [Related]  

  • 20. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria.
    Ruth MM; Sangen JJN; Remmers K; Pennings LJ; Svensson E; Aarnoutse RE; Zweijpfenning SMH; Hoefsloot W; Kuipers S; Magis-Escurra C; Wertheim HFL; van Ingen J
    J Antimicrob Chemother; 2019 Apr; 74(4):935-943. PubMed ID: 30649327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.